Inozyme Pharma Inc Ordinary Shares INZY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INZY is a good fit for your portfolio.
News
-
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
-
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
-
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
-
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
-
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
-
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $4.33
- Day Range
- $4.23–4.51
- 52-Week Range
- $2.69–7.80
- Bid/Ask
- $4.23 / $4.69
- Market Cap
- $274.27 Mil
- Volume/Avg
- 511,357 / 693,931
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 59
- Website
- https://www.inozyme.com
Comparables
Valuation
|
Metric
|
INZY
|
VRDN
|
SWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.95 | 2.95 | 5.19 |
Price/Sales | — | 1,835.80 | 512.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
INZY
VRDN
SWTX
Financial Strength
|
Metric
|
INZY
|
VRDN
|
SWTX
|
|---|---|---|---|
Quick Ratio | 12.87 | 17.93 | 6.21 |
Current Ratio | 13.36 | 18.26 | 6.41 |
Interest Coverage | −22.70 | −137.76 | — |
Quick Ratio
INZY
VRDN
SWTX
Profitability
|
Metric
|
INZY
|
VRDN
|
SWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −38.23% | −42.76% | −39.61% |
Return on Equity (Normalized) | −51.04% | −82.42% | −45.43% |
Return on Invested Capital (Normalized) | −44.20% | −50.70% | −49.28% |
Return on Assets
INZY
VRDN
SWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rvpgvxwdl | Fbtd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yddwcsgrv | Tkngjcw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pnsrtsy | Zvnvdmx | $97.8 Bil | |
MRNA
| Moderna Inc | Pszmnfp | Klgc | $41.3 Bil | |
ARGX
| argenx SE ADR | Pglrfrvx | Qyn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nybdmcrxs | Ghpl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zxfwvytqt | Pcpsf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pvpswkq | Grcqyqt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Twcrkyzfz | Jpdkx | $12.5 Bil | |
INCY
| Incyte Corp | Ysfkjtdf | Rjhrxys | $11.6 Bil |